Fatukasi Terra V, Cole Stephen R, Moore Richard D, Mathews William C, Edwards Jessie K, Eron Joseph J
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
PLoS One. 2017 Jul 10;12(7):e0180843. doi: 10.1371/journal.pone.0180843. eCollection 2017.
Prompt initiation of combination antiretroviral therapy (ART) is important to reduce comorbidity and mortality among people living with HIV, especially for those with a low CD4 cell count. However there is evidence that not everyone receives prompt initiation of ART after enrolling into HIV care. The current study investigated factors associated with failure to initiate ART within two years of entering into care among those with a CD4 count at or below 350 cells/mm3. The sample included 4,907 ART-naive patients with a CD4 count at or below 350 cells/mm3 enrolled between January 1, 2003 and December 31, 2012 at any of eight clinical sites in the Center for AIDS Research Network of Integrated Clinical Systems (CNICS). The two-year risk of delayed ART initiation was estimated using a log-binomial regression model with stabilized inverse probability of censoring weights for those lost to follow-up. Adjusting for other factors, an earlier enrollment date was the sole demographic characteristic associated with an increased risk of delayed ART initiation. Higher CD4 count, lower viral load, and a prevalent AIDS diagnosis were clinical characteristics associated with delayed ART initiation. Gender, age, race/ethnicity and HIV risk factors such as reported male-to-male sexual contact and injection drug use were not associated with delayed ART initiation. This study identified characteristics of patients for whom treatment was strongly to moderately recommended but who did not initiate ART within two years of entering care. Despite the known benefits of early antiretroviral therapy initiation, a lower viral load measurement may continue to be an important clinical characteristic in the more recent era with current ART initiation guidelines. These findings provide a target for closer monitoring and intervention to reduce disparities in HIV care.
及时启动抗逆转录病毒联合疗法(ART)对于降低HIV感染者的合并症和死亡率非常重要,尤其是对于那些CD4细胞计数低的患者。然而,有证据表明,并非每个人在进入HIV护理后都能及时开始接受ART治疗。本研究调查了CD4细胞计数等于或低于350个细胞/立方毫米的患者在进入护理后两年内未开始接受ART治疗的相关因素。样本包括2003年1月1日至2012年12月31日期间在综合临床系统艾滋病研究网络(CNICS)的八个临床站点中的任何一个登记的4907名未接受过ART治疗且CD4细胞计数等于或低于350个细胞/立方毫米的患者。使用对数二项回归模型估计延迟开始ART治疗的两年风险,并对失访者采用稳定的逆删失概率权重。在调整其他因素后,较早的登记日期是与延迟开始ART治疗风险增加相关的唯一人口统计学特征。较高的CD4细胞计数、较低的病毒载量和已确诊的艾滋病是与延迟开始ART治疗相关的临床特征。性别、年龄、种族/族裔以及HIV风险因素,如报告的男男性接触和注射吸毒,与延迟开始ART治疗无关。本研究确定了那些强烈或中度推荐接受治疗但在进入护理后两年内未开始接受ART治疗的患者的特征。尽管已知早期开始抗逆转录病毒治疗有好处,但在当前的ART启动指南下,较低的病毒载量测量值在最近的时代可能仍然是一个重要的临床特征。这些发现为加强监测和干预以减少HIV护理差异提供了一个目标。